Benefits of luteinizing hormone activity in ovarian stimulation for IVF

Abstract Knowledge of the physiology of folliculogenesis has led to a better understanding of the role of LH activity in this process. This role has been investigated in the setting of ovarian stimulation and several treatment modalities have been proposed. LH activity can be provided in the forms o...

Full description

Saved in:

Bibliographic Details
Published in:	Reproductive biomedicine online Vol. 18; pp. S31 - S36
Main Authors:	Venetis, CA, Kolibianakis, EM, Tarlatzi, TB, Tarlatzis, BC
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 2009
Subjects:	Chorionic Gonadotropin - therapeutic use Female Fertility Agents, Female - therapeutic use Fertilization in Vitro Follicle Stimulating Hormone - therapeutic use Gonadotropin-Releasing Hormone - therapeutic use human chorionic gonadotrophin human menopausal gonadotrophin Humans in-vitro fertilization Luteinizing Hormone - physiology Luteinizing Hormone - therapeutic use luteinizing hormone activity Menotropins - therapeutic use Obstetrics and Gynecology ovarian stimulation Ovulation Induction Pregnancy Pregnancy Rate Recombinant Fusion Proteins - therapeutic use Reproductive Control Agents - therapeutic use human menopausal gonadotrophin human chorionic gonadotrophin in-vitro fertilization luteinizing hormone activity ovarian stimulation
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Knowledge of the physiology of folliculogenesis has led to a better understanding of the role of LH activity in this process. This role has been investigated in the setting of ovarian stimulation and several treatment modalities have been proposed. LH activity can be provided in the forms of: (i) human menopausal gonadotrophins (HMG), (ii) recombinant LH (rLH), (iii) human chorionic gonadotrophin (HCG), and (iv) recombinant HCG (rHCG). Current evidence suggests that ovarian stimulation performed with HMG in patients treated with a long gonadotrophin releasing hormone (GnRH) agonist protocol seems to result in increased (3–4%) clinical pregnancy rates compared with recombinant FSH (rFSH). Data regarding the short GnRH agonist or GnRH antagonist protocol are scarce and firm conclusions cannot be drawn. Administration of rLH prior or during ovarian stimulation with rFSH does not seem to increase the probability of pregnancy. Existing data suggest that HCG is capable of partially or completely replacing FSH administration during the mid-to-late follicular phase of an ovarian stimulation cycle, leading to a decreased requirement for FSH, without compromising pregnancy rates. High quality evidence originating from randomized controlled trials regarding the potential value of rHCG administration during ovarian stimulation for IVF is not available.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1472-6483 1472-6491
DOI:	10.1016/S1472-6483(10)60446-4